Another Infliximab Biosimilar On Horizon In India?

 
• By Anju Ghangurde

More competition appears to be in the wings for Remicade in India after the Russian firm Biocad’s biosimilar infliximab was endorsed in India by an expert panel, though there’s little clarity on launch specifics, at least for now.

Eclipse
BIOCAD'S INFLIXIMAB HAS RECEIVED A KEY APPROVAL IN INDIA BUT LAUNCH PLANS ARE HAZY • Source: Shutterstock

More from India

More from Focus On Asia